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Abstract  
This study assesses whether C-terminal fragments (CTF) of the amyloid precursor 
protein (APP) are present in cerebrospinal fluid (CSF) and their potential as biomarkers 
for Alzheimer’s disease (AD). We demonstrate that APP-CTFs are detectable in human 
CSF, the most abundant being a 25-kDa fragment, probably resulting from proteolytic 
processing by η-secretase. The CSF level of this 25-kDa CTF is higher in subjects with 
autosomal dominant AD patients linked to PSEN1 mutations, in demented Down 
syndrome individuals and in sporadic AD subjects compared to age-matched controls. 
Our data suggest that APP-CTF could be a potential diagnostic biomarker for AD. 
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Background  
Accumulation of the β-amyloid peptide (Aβ) in the brain is an early and specific 
phenomenon associated with the pathogenesis of Alzheimer’s disease (AD) (Scheltens 
et al., 2016). Many reports support that the determination of Aβ42 in cerebrospinal fluid 
(CSF) is a core biomarker for AD (Blennow et al., 2015). While the amount of the 
pathological species of Aβ is increased in the AD brain, their levels in CSF are 
decreased, probably due to increased brain deposition. To enable monitoring early 
disturbance in amyloid precursor protein (APP) and Aβ mis-metabolism additional 
biomarkers are needed. 
Other plausible biomarkers for AD are additional fragments resulting from the 
processing of the amyloid precursor protein (APP), which may contribute to Aβ 
deposition in the AD brain. APP is a large type I transmembrane spanning protein 
consisting of a large N-terminal extracellular domain, a hydrophobic transmembrane 
domain, and a short intracellular C-terminal domain. APP is usually cleaved by α-
secretase (ADAM10; leading to non-amyloidogenic pathway), or by β-secretase 
(BACE1; leading to amyloidogenic pathway), which causes the secretion of large 
sAPPα and sAPPβ N-terminal fragments (NTFs). CSF levels of sAPPα and sAPPβ 
show no change in AD (Olsson et al., 2016). The membrane remaining C-terminal 
fragments (CTFs) are always processed by γ-secretase generating shortest intracellular 
domain (AICD) peptides (for a review see Haass et al., 2012). 
APP can also undergo alternative proteolytic processing pathways (see recent 
review Andrew et al., 2016). Thereby, concerted cleavage of β-secretase and α-secretase 
result in the secretion of sAPPβ and shorter A peptides (Portelius et al., 2011). The 
presence in CSF of short NTF derivatives of APP, which generation does not involve α-
secretase or BACE, has been also demonstrated (Portelius et al., 2010). More 
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interestingly in the context of this report, a recently discovered alternative physiological 
APP processing pathway driven by an asparagine endopeptidase named δ-secretase 
(Zang et al., 2015) or by a metalloproteinase named η-secretase (Willen et al., 2015) 
will generate alternative proteolytic metabolites, including NTFs and CTFs, of different 
molecular mass. 
In addition to the different species of A, all the large extracellular APP-NTFs 
have been studied in human CSF (Palmert et al., 1989; Ghiso et al., 1989; Willen et al., 
2015); but the presence of APP-CTFs in CSF has not been reported to date. In this study 
we investigated if APP-CTFs are detectable in CSF, characterized the major APP-CTF 
immunoreactive band, and determined whether the levels of this peptide fragment are 
altered in autosomal dominant AD (ADAD), Down syndrome subjects with 
Alzheimer’s type dementia (dDS), and sporadic AD subjects (sAD).  
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Material and methods  
Patients 
Lumbar CSF samples were obtained from ADAD subjects that were all carriers of 
PSEN1 mutations and who were part of the Genetic Counseling Program for familiar 
dementia (PICOGEN) at the Hospital Clínic (Barcelona, Spain). This group included 7 
subjects carrying PSEN1 mutations, and 7 age-matched non-mutation carriers from the 
same families (non-disease controls: NC). We also included lumbar CSF samples from 
7 dDS subjects, along with 7 age-matched NC obtained from the Hospital Sant Pau 
(Barcelona, Spain). In addition, 20 patients with sAD defined as patients with cognitive 
symptoms and a CSF biomarker profile indicating AD (high total tau and 
phosphorylated tau together with low Aβ42 levels; see Supplemental Table 1) and 20 
age-matched controls defined as (patients with non-specific symptoms without 
neurochemical evidence of AD) were also obtained from the Clinical Neurochemistry 
Laboratory (Mölndal, Sweden). All AD patients fulfilled the 2011 NIA-AA criteria for 
dementia (McKann et al., 2011).  
 
Western blotting and immunoprecipitation 
Samples of CSF (30 µL) were denatured at 98ºC for 5 min and were resolved by 
electrophoresis on 16.5% Tris-Tricine gels. Following electrophoresis, proteins were 
blotted onto nitrocellulose membranes (Schleicher & Schuell Bioscience, GmbH). CTFs 
of APP were detected using the following anti-APP C-terminal antibodies: C1/6.1 
(mouse monoclonal; Covance), A8717 (rabbit polyclonal; Sigma), and Y188 (rabbit 
monoclonal; Abcam), as well as with the rat antibodies 2D8 and 2E9 (Willem et al., 
2015). To assess the specificity of the immunoreactive bands, samples were resolved by 
simultaneous detection of immunoreactivity to two antibodies. Blots were then probed 
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with the appropriate conjugated secondary antibodies and imaged on an Odyssey Clx 
Infrared Imaging System (LI-COR). Band intensities were analyzed using LI-COR 
software (Image Studio Lite). A control CSF sample was used to normalize the 
immunoreactive signal between blots. 
For immunoprecipitation, samples were precleared for 2 h at 4 ºC by incubation 
with protein A-Sepharose (Sigma-Aldrich). Immunoprecipitations were performed at 
4ºC by incubating 150 µL of CSF, overnight with the indicated anti-APP antibody 
previously coupled to protein A-Sepharose using dimethyl pimelimidate 
dihydrochloride (Sigma-Aldrich Co). Precipitated proteins were washed with PBS and 
eluted with 0.1M glycine buffer at pH 2.5. After pH neutralization, supernatants were 
denatured in Laemmli sample buffer at 98ºC for 5 min and subjected to SDS-PAGE. 
The membranes were then probed with an alternative anti-APP antibody. 
 
Measurement of T-tau, P-tau and Aβ42 by ELISA 
Total tau (T-tau), phosphorylated tau (P-tau) and Aβ1-42 (Aβ42) concentrations in CSF 
were measured using INNOTEST ELISA methods (Fujirebio Europe). 
 
Statistical analysis  
All data were analyzed using SigmaStat (Version 3.5; Systac Software Inc.) by 
Student’s t test (two-tailed) for determination of exact p values. Correlation was 
assessed by linear regression. Results are presented as means ±SEM. 
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Results 
APP-CTFs are present in human CSF 
To determine the presence of APP-CTFs in human CSF, we first examined human CSF 
samples by Western blotting using three different anti-CTF antibodies (a schematic 
representation of APP and epitopes for antibodies is represented in Fig. 1A). 
Immunoblotting revealed a similar pattern of immunoreactive bands, with a 
predominant band of ~25 kDa (Fig. 1B). This band was also observed with the 2D8 and 
2E9 antibodies, both against an extracellular domain close to the transmembrane 
domain, thus recognizing a η-secretase-generated CTF-APP (CTFη) (Willem et al., 
2015). Simultaneous assay of combined fluorescence with the A8717 and 2E9 
antibodies indicated that the major 25 kDa band is compatible with the CTFη; similar 
co-labelling was revealed with antibodies C1/6.1 and 2D8 (Supplemental Fig. 1). To 
further examine the identity of CTF bands in human CSF, we performed 
immunoprecipitation/Western blot analysis (Fig. 1C). CSF samples were 
immunoprecipitated using the A8717 antibody and blotted with the Y1887 antibody, 
confirming the identity of the 25-kDa band as an APP-CTF. Immunoprecipitating with 
2D8 antibody and blotting with A8717 antibody confirmed the 25-kDa band as a CTFη. 
 
The 25-kDa CTFη is increased in AD CSF 
To assess whether APP-CTF levels are altered in AD, we first analyzed CSF samples 
from genetically determined AD subjects. The 25-kDa band was detected with A8717 
antibody in all CSF analyzed (Fig. 2A). The level of the 25-kDa APP-CTF band in the 
CSF from ADAD subjects increased (95±27%; p= 0.01) compared to those in age-
matched NC composed by non-mutation carriers from the same families (Fig. 2A). DS 
is also considered a pre-symptomatic AD (Dubois et al., 2014). Once more, an increase 
García-Ayllón et al. 9
(68±18%; p= 0.01) in the level of the 25-kDa APP-CTF band was determined in CSF 
samples from dDS patients, comparing these to age-matched NC (Fig. 2B). Finally, we 
found that the immunoreactivity for this band increases (35±9%; p= 0.01) in sAD 
compared to age-matched NC subjects (Fig. 2C). CSF samples from sAD subjects also 
showed similar increases for the 25-kDa band when analyzed with the 2D8 antibody 
(35±9%; p= 0.01), correlating tightly the estimation of the levels calculated with the 
A8717 antibody (Supplemental Fig. 2).  
 
Discussion  
Here, we demonstrate that APP-CTFs are detectable in human CSF. Particularly, the 
most abundant soluble APP-CTF is attributable to 25-kDa CTF recently characterize as 
the result of proteolytic processing by η-secretase (Willem et al., 2015). Canonical APP 
proteolysis occurs via α- and β-secretases, resulting  in CTFα and CTFβ with a 
molecular mass lower than 15 kDa; but novel APP-CTF that migrate ~25 kDa have 
been described (Wang et al., 2015). As an intermediate of proteolytic process, the 
presence of any APP-CTF in CSF was unexpected. Anyhow, the presence in CSF of 
soluble forms of full-length membrane proteins containing the transmembrane and 
intracellular domains is not an unusual finding (Lopez-Font et al., 2015). The 
mechanisms by which these membrane-bound proteins reached the CSF are unknown, 
but neuronal death may be a major contributing factor. 
 Different APP C-terminal antibodies confirmed the 25 kDa CTFη as the 
predominant band in human CSF. As stated, these APP proteolytic fragments are 
derived from a constitutive processing step driven by a η-secretase that is partially in 
dynamic equilibrium with α- and β-secretase-mediated proteolysis (Haass et al., 1992; 
Willem et al., 2015; Lauritzen et al., 2016). The current canonical views about APP-
related cleavage events are likely a partial understanding of the overall process. How 
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secretases compete for the APP substrate and whether subcellular compartmentalization 
of APP and secretases is responsible of the dynamic equilibrium between secretases is 
under discussion (Gandhi et al., 2004). Thus, one may speculate that the particular 
abundance of the 25-kDa CTFη in CSF is related with compartmentalization of 
secretases, resulting in prolonged time of residence of these CTFη in comparison with 
canonical CTFα and CTFβ. Anyhow, the other fragments derived of the further 
processing of CTFη by α- and β-secretases, the Aη-α and Aη-β fragments, have been 
also identified in human CSF with levels similar than those for Aβ (Willem et al., 
2015). 
Our determination of the CTFη-CTF levels by Western blotting displayed large 
overlap for sAD, whereas superior discrimination was obtained for ADAD and dDS 
subjects. Interestingly, APP CTFβ levels are also in frontal cortex brain homogenates 
obtained from patients (Pera et al., 2013). Further studies will indicate if distinct pattern 
of APP processing in ADAD and sAD affect the generation of different APP-CTFs. In 
our study all the pathological groups were compared with age-matched controls 
obtained from the same center of sample collection. The possibility that APP-CTF 
levels varies with age should be considered and deserve a specific study with larger 
number of samples. In any case, it will be valuable to replicate these finding using 
techniques such as ELISA, to evaluate their true potential as biomarkers. However, this 
desirable outcome will be challenging. We have described that the soluble full-length 
APP, containing the C-terminal domain, also exists in CSF as heteromeric complexes 
compromising other sAPP species (Cuchillo-Ibañez et al., 2015), and transmembrane 
domain, as well intracellular C-terminal domain could participate in APP dimerization 
(discussed in Isbert et al., 2012). Thus, future studies should develop custom pan-
specific antibodies targeting the predicted N-terminal sequence of the APP-CTFs 
present in CSF for preventing co-precipitation of other APP fragment. Anyhow, even 
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the disadvantages of Western blotting for quantitative analysis, we considered that 
based on the data present in this study, there are sufficient evidence to justify further 
studies on the determination of APP-CTFs as a potential diagnostic biomarker of AD. 
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Figure Legends 
Figure 1. Soluble CTFs of APP are present in human CSF. (A) Schematic 
representation of full-length APP processing by secretases. The epitopes for the 
antibodies used in this study are indicated. (B) Western blotting of three human CSF 
samples from non-demented controls subjects, resolved with the indicated antibody.  
2D8 and 2E9 also detect other soluble fragments around ~15 kDa, termed Aη, generated 
after concerted cleavage by η-secretase and α/β-secretases (see Willem et al., 2015). 
2D8 antibody also detects Aβ monomers. (C) CSF aliquots (Total, T) were 
immunoprecipitated with the indicated antibody and precipitated proteins (bound 
fraction, IP) were immunoblotted with the indicated alternative antibody. In the absence 
of capture-antibody (IPc), no bands were observed. 
 
Figure 2. Higher levels of the 25-kDa APP-CTF band in the CSF of AD subjects. 
(A) Representative blot of the APP-CTF in the CSF samples from 7 symptomatic 
ADAD and 7 age-matched NC, which were from the same families that ADAD subjects 
but that did not carry mutations (black symbol; see also Table 1). Densitometric 
quantification of the immunoreactivity from the 25-kDa band is also shown. (B) 
Representative blot and densitometric quantification in CSF from 7 DS subjects with 
dementia of the Alzheimer's type (dDS) and 7 age-matched NC. (C) Representative blot 
and densitometric quantification of the immunoreactivity from the 25-KDa APP-CTF in 
CSF samples from 20 sAD and 20 age-matched NC subjects. Immunodetection was 
performed with the A8717 antibody. p values are displayed. 
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Supplemental Figure 1. SDS-PAGE analysis and fluorescence detection of soluble 
CTFs of APP in human CSF. To probe that the 25-kDa specie resolved with different 
antibodies is the same, three aliquots of CSF were analyzed by SDS-PAGE and 
resolved with (A) A8717 and 2E9 antibodies, or (B) C1/6.1 and 2D8 antibodies, 
simultaneously. The fluorescence of the secondary antibodies was detected with the 
Odyssey CLx Infrared Imaging system (LI-COR). 
 
Supplemental Figure 2. Corroboration of the increase in the 25-kDa APP-CTF in 
the CSF of sAD subjects. Representative blot and densitometric quantification of the 
25-kDa APP-CTF in the CSF samples from 20 probable sAD 20 age-matched NC 
subjects blotted with the A8717 antibody (same data that in Fig. 2) and with the 2D8 
antibody. A positive correlation was obtained when immunoreactive levels estimated 
with both antibodies from the same subjects were confronted. Regression linear 
coefficient (R) and p values are displayed.
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Table 1: Clinical, demographic data and classic CSF biomarker levels.  
 
Group Age 
(years) 
Gender CSF Aβ42 
(pg/mL) 
CSF T-tau 
(pg/mL) 
CSF P-tau 
(pg/mL) 
sAD 
 
71±2 [55-86] 
 
15F/5M 
 
412±19** 
 
665±52** 
 
84±6** 
 
NC 
    
72±2 [57-88] 
 
6F/14M 739±32 233±14 36±2 
 
 
ADAD 
    
43±2 [31-49] 
 
5F/2M 266±49** 883±204** 168±69* 
 
NC 
    
39±3 [25-47] 
 
5F/2M 809±94 245±29 46±4 
 
      
dDS 
 
53±2 [43-57] 
 
4F/3M 422±17* 767±170* 108±19* 
 
NC 
 
48±2 [47-53] 
 
5F/2M 751±84* 160±26 33±5 
 
 
The PSEN1 mutations included in this study from ADAD cases (autosomal dominant 
AD subjects) corresponded to 3 carriers of L286P, and one S169P, L173F, L235R and 
L282R. The data represent the means ±SEM, and for age the range of values is also 
indicated. All the pathological groups were compared with age-matched NC obtained 
from the same Hospital. Significantly different **p< 0.005; *p< 0.05 from the NC 
group. This study was approved by the ethics committee at the Miguel Hernandez 
University and it was carried out in accordance with the Declaration of Helsinki. 
